FluCamp is all about improving the health of the population, through increasing understanding around common viral illnesses.
Ultimately, the more that we understand about how viruses affect the human immune system, the more quickly we can find and test better ways to treat them. The end goal of clinical trials like those we conduct at FluCamp is to potentially eradicate these common illnesses completely – or at least make treatment of them as easy and effective as possible.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).